摘要
目的 探讨重组人类促红细胞生成素 (rHu Epo)防治早产儿贫血的临床效果。方法 2 0例早产儿随机分成两组 ,治疗组和对照组各 10例。两组早产儿出生后第 2天开始口服铁剂 (元素铁 5mg·kg-1·d-1) ,共观察 4周。治疗组出生第 2周开始给予rHu Epo 2 0 0IU/(kg·次 ) ,皮下注射 ,隔日 1次 ,每周 3次 ,共 4周。结果 治疗前两组间Hb、血清铁蛋白 (SF)比较均无差异 ,P值均 >0 .0 5。治疗结束后两组血红蛋白 (Hb)均下降 ,但对照组Hb明显低于治疗组 (P <0 .0 1)。治疗结束后两组血清铁蛋白 (SF)均降低 ,与治疗前比较 ,P值均 <0 .0 5 ,但治疗后两组间SF无统计学差异 ,P >0 .0 5。结论 rHu Epo能减轻早产儿贫血的程度 ,并可能减少输血。
Objective To assess the efficacy of recombinant human erythropoietin (rhEPO)in reducing postnatal hemoglobin decline in premature infants,and in reducing the need for transfusion.Methods A prospective,controlled,randomized trial lasting 4 weeks were performed in 20 clinically stable premature less than 35 weeks gestation.All participants were randomized to receive 28 days of treatment with daily oral iron 5mg/(kg·d) and 10 of them (EPO-treated group)with 200U/(kg·t) of rhEPO and daily oral iron 5mg/(kg·d).Blood samples were analyzed for hemoglobin(Hb),and serum levels of ferritin(SF).Results At the end of treatment,Hb,sTfR were markedly higher in the EPO-treated group,compared with the oral iron group(control group),but SF was lower after treatment than before in all the babies and existed no difference between control group with EPO-treated group both before and after treatment.10% of EPO-treated infants VS 30% of control infants received transfusion.Conclusion It is concluded that rhEPO therapy is efficient in premature babies with 200U/(kg·t) rhEPO and may be it can reduce the need for blood transfusions.
出处
《四川医学》
CAS
2004年第11期1196-1197,共2页
Sichuan Medical Journal
基金
四川省卫生厅科研基金资助项目 (0 0 0 1 84)
